{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-23-000117","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.841771+00:00","generated_at":"2026-06-09T06:12:10.633541+00:00","sec_items":["1.01","1.02","2.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LianBio terminates mavacamten license for $350M; TP-03 Phase 3 shows mixed results","bullets":["Terminated mavacamten license with BMS/MyoKardia; receives $350M payment and released from $127.5M in milestones.","Phase 3 LIBRA trial met co-primary endpoint of mite eradication (p<0.001) but missed collarette cure (p=0.15).","Plans to discuss TP-03 results with NMPA and expects to file NDA for Demodex blepharitis in China.","Pro forma cash and equivalents rise to $444M (from $104M) after termination payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-23-000117","json":"https://secwatch.observer/filing/0001831283-23-000117.json","markdown":"https://secwatch.observer/filing/0001831283-23-000117.md","text":"https://secwatch.observer/filing/0001831283-23-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/0001831283-23-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/lian-20231024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:12:10.633541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe191de4955a01d7b32ade93c1fa95ae053ddb67","claim":"LianBio completed a disposition involving MyoKardia, Inc. and Bristol-Myers Squibb Company for $350 million (closed 2023-10-24).","evidence_excerpt":"Pursuant to the Termination Agreement, LianBio will receive a one-time payment of $350 million as consideration for the Transaction.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/0001831283-23-000117-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"MyoKardia, Inc. and Bristol-Myers Squibb Company"},{"label":"Consideration","value":"$350 million"},{"label":"Closing","value":"2023-10-24"}],"fact_type":"ma_transaction"},{"claim_id":"48e737f9081e30d2dafb95433375cfc6d375898c","claim":"LianBio terminated License Agreement with MyoKardia, Inc. and Bristol-Myers Squibb Company valued at $350 million (effective 2023-10-24).","evidence_excerpt":"On October 24, 2023 (the “Termination Effective Date”), LianBio entered into a Termination Agreement, dated October 24, 2023 (the “Termination Agreement”), by and among MyoKardia, Inc. (“MyoKardia”) and Bristol-Myers Squibb Company","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/0001831283-23-000117-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"MyoKardia, Inc. and Bristol-Myers Squibb Company"},{"label":"Value","value":"$350 million"},{"label":"Effective","value":"2023-10-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}